Enrupatinib

N/A

Report date: 2026/01/16 10:34:27
NME

Base Information

Drug NameEnrupatinib
Drug Alias NameEI-1071FB-10714B71-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionColony stimulating factor 1 receptor inhibitors
TargetsColony stimulating factor 1 receptor
Therapy Area/IndicationsAmyotrophic Lateral SclerosisAlzheimer DiseaseNervous System Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesElixiron Immunotherapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesElixiron Immunotherapeutics IncElixiron Immunotherapeutics LtdFubei Biomedical Technology (Beijing) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisAlzheimer DiseaseGiant Cell Tumor of Tendon Sheath
Inactive IndicationsNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A